Journal of Gastrointestinal Surgery

, Volume 19, Issue 11, pp 2038–2044 | Cite as

Octreotide Does Not Prevent Pancreatic Fistula Following Pancreatoduodenectomy in Patients with Soft Pancreas and Non-dilated Duct: A Prospective Randomized Controlled Trial

  • Prakash Kurumboor
  • Kamalesh Nadothottam Palaniswami
  • K. Pramil
  • Deepak George
  • Shaji Ponnambathayil
  • Deepak Varma
  • Sylesh Aikot
Original Article

Abstract

Background

Whether octreotide prevents pancreatic fistula following pancreatoduodenectomy is controversial and it is believed to be beneficial in soft glands and normal-sized ducts. The aim of this study is to assess the potential value of octreotide in reducing the incidence of pancreatic fistula, postoperative complications, morbidity and hospital stay in patients with soft pancreas and non-dilated ducts.

Methods

A total of 109 patients undergoing elective pancreatoduodenectomy with soft pancreas and non-dilated duct were randomized to octreotide group versus no octreotide—the control group. Surgical steps were standardized and incidences of pancreatic fistula, complications, death and hospital stay were assessed.

Results

There were 55 patients in octreotide group and 54 in the control group. Demographic features and pancreatic duct diameter of the groups were comparable. The rates of clinically significant pancreatic fistulae (grades B and C) were 10.9 and 18.5 % (p = ns), and morbidity was 18 and 29.6 % (p = ns), respectively. Patients who received octreotide resumed oral diet early and had a shorter hospital stay.

Conclusion

This study demonstrated no statistical difference in pancreatic fistulae with the use of octreotide, though there was a trend towards fewer incidences of pancreatic fistulae, morbidity and shorter hospital stay.

ClinicalTrials.gov Identifier: NCT01301222

Keywords

Pancreatic fistula Octreotide Pancreaticoduodenectomy Randomized controlled trial 

References

  1. 1.
    Yeo CJ, Cameron JL, Sohn TA, K D Lillemoe, H A Pitt, M A Talamini, Hruban RH, Ord SE, Sauter PK, Coleman J, Zahurak ML, Grochow LB, Abrams RA. Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: Pathology, complications and outcomes. Ann Surg 1997; 226:248–257.PubMedCentralCrossRefPubMedGoogle Scholar
  2. 2.
    Ho V, Heslin MJ. Effect of hospital volume and experience on in hospital mortality for pancreaticoduodenectomy. Ann Surg2003; 237:509–514.PubMedCentralPubMedGoogle Scholar
  3. 3.
    Crist DW, Sitzmann JV, Cameron JL. Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann Surg1987; 206:358–65.PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    Gouma DJ, van Geenen RC, van Gulik TM, Thomas M, de Haan RJ, de Wit LT, Busch, ORC, Obertop, HL. Rates of complications and death after pancreaticoduodenectomy: risk factors and the impact of hospital volume. Ann Surg 2000;232: 786–795.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006; 244: 10–15.PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    Bassi C, Falconi M, Salvia R, Mascetta G, Molinari E, Pederzoli P. Management of complications after pancreaticoduodenectomy in a high volume centre: Results on 150 consecutive patients. Dig Surg 2001; 18:453–458.CrossRefPubMedGoogle Scholar
  7. 7.
    Poon RT, Lo SH, Fong D, Fan ST, Wong J. Prevention of pancreatic anastomotic leakage after pancreaticoduodenectomy. Am J Surg2002; 183:42–52.CrossRefPubMedGoogle Scholar
  8. 8.
    Yeh TS, Jan YY, Jeng LB, Hwang TL, Wang CS, Chen SC, Chao TC, Chen MF. Pancreaticojejunal anastomotic leak after pancreaticoduodenectomy—multivariate analysis of perioperative risk factors. J Surg Res 1997; 67:119–125.CrossRefPubMedGoogle Scholar
  9. 9.
    N. Sato, K. Yamaguchi, K. Chijiiwa, and M. Tanaka, “Risk analysis of pancreatic fistula after pancreatic head resection,” Archives of Surgery 1998; 133(10): 1094–1098.CrossRefPubMedGoogle Scholar
  10. 10.
    Klempa I, Schwedes U, Usadel KH. Prevention of postoperative pancreatic complications following duodenopancreatectomy using somatostatin. Chirurg 1979; 50:427–31.PubMedGoogle Scholar
  11. 11.
    Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci1982; 31:1133–40.CrossRefPubMedGoogle Scholar
  12. 12.
    Bassi C, Dervenis C, Butturini G, Fingerhut A, Yeo C, Izbicki J, Neoptolemos J, Sarr M, Traverso W, Buchler M. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 2005; 138:8–13.CrossRefPubMedGoogle Scholar
  13. 13.
    GurusamyKS, Koti R, FusaiG, Davidson BR. Somatostatin analogues for pancreatic surgery. CochraneDatabase of Systematic Reviews 2013, Issue 4. Art. No.: CD008370.Google Scholar
  14. 14.
    Friess H, Beger HG, Sulkowski U, Becker H, Hofbauer B, Dennler HJ, Büchler MW. Randomized controlled multicentre study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitis. Br J Surg 1995; 82:1270–1273.CrossRefPubMedGoogle Scholar
  15. 15.
    Buchler M, Friess H, Klempa I,Hermanek P, Sulkowski U, Becker H, Schafmayer A, Baca I, Lorenz D, Meister R. Role of octreotide in the prevention of postoperative complications following pancreaticresection. Am J Surg1992;163:125–30.Google Scholar
  16. 16.
    Pederzoli P, Bassi C, Falconi M,Camboni MG. Efficacy of octreotide in the prevention of complications of elective pancreaticsurgery. Br J Surg1994; 81:265–9.Google Scholar
  17. 17.
    Lowy AM, Lee JE, Pisters PW,Davidson BS, Fenoglio CJ, Stanford P, Jinnah R, Evans DB. Prospective, randomized trial of octreotide to prevent pancreatic fistula after pancreaticoduodenectomy for malignant disease. Ann Surg1997; 226:632–41.PubMedCentralCrossRefPubMedGoogle Scholar
  18. 18.
    Yeo CJ, Cameron JL, Lillemoe KD, Sauter PK, Coleman J, Sohn TA, Campbell KA, Choti MA. “Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial,” Annals of Surgery 2000; 232(3): 419–429.PubMedCentralCrossRefPubMedGoogle Scholar
  19. 19.
    Hesse UJ, De Decker C, Houtmeyers P, Demetter P, Ceelen W, Pattyn P, Troisi R, deHemptinne B. Prospectively randomized trialusing perioperative low-dose octreotide to prevent organ related and general complications after pancreatic surgery and pancreatico-jejunostomy. World Journal of Surgery 2005; 29(10):1325–8.Google Scholar
  20. 20.
    Kollmar O, Moussavian MR, Richter S, de Roi P, Maurer CA, Schilling MK. Prophylactic octreotide and delayed gastric emptying after pancreaticoduodenectomy: results of a prospective randomized double-blinded placebo controlled trial. European Journal of Surgical Oncology 2008; 34(8):868–75.CrossRefPubMedGoogle Scholar
  21. 21.
    Gouillat C, Chipponi J, Baulieux J, Partensky C, Saric J, Gayet B. Randomized controlled multicentre trial of somatostatin infusion after pancreaticoduodenectomy. Br J Surg 2001;88(11):1456–62.CrossRefPubMedGoogle Scholar
  22. 22.
    Koti RS, Gurusamy KS, Fusai G, Davidson BR. Metaanalysis of randomized controlled trials on the effectiveness of somatostatin analogues for pancreatic surgery: A Cochrane review. HPB 2010;12(3):155–65.PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    McMillan MT, Christein JD, Callery MP, Behrman SW, Drebin JA, Kent TS, Miller BC, Lewis RS Jr, Vollmer CM Jr. Prophylactic octreotide for pancreatoduodenectomy: more harm than good? HPB 2014, 16, 954–962.PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Fernández-Cruz L, Chavarría EJ, Taura P, Closa D, López-Boado MA, Ferrer J. Prospective randomized trial of the effect of octreotide onpancreatic juice output after pancreaticoduodenectomy inrelation to histological diagnosis, duct size and leakage. HPB 2013, 15, 392–399.Google Scholar
  25. 25.
    Lembcke B, Creutzfeldt W, Schleser S, Ebert R, Shaw C, Koop I. Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men. Digestion 36:108–124.Google Scholar
  26. 26.
    Fuessl HS, Carolan G, Williams G, Bloom SR. Effect of a long-acting somatostatin analogue (SMS 201–995) on postprandial gastric emptying of 99mTc-tin colloid andmouth-to-caecum transit time in man. Digestion 1987; 36: 101–7.Google Scholar
  27. 27.
    Gaujoux S, Cortes A, Couvelard A, Noullet S, Clavel L, Rebours V Lévy P, Sauvanet A, Ruszniewski P, Belghiti J. Fatty pancreas and increased body mass index are risk factors of pancreatic fistula after pancreaticoduodenectomy. Surgery 2010;148:15–23.CrossRefPubMedGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2015

Authors and Affiliations

  1. 1.Department of GI SurgeryPVS Memorial Hospital, KaloorKochiIndia

Personalised recommendations